Paxlovid (nirmatrelvir/ritonavir) is a novel, orally administered inhibitor of the 3-chymotrypsin-like cysteine protease (Mpro) of SARS-CoV-2. Nirmatrelvir is primarily metabolized by CYP3A4 and is administered with ritonavir as a pharmacokinetic enhancer. Coadministration of Paxlovid and certain drugs can result in potentially significant drug interactions. Paxlovid is contraindicated with certain drugs due to serious adverse reactions. Such interactions need to be managed through dose reduction of the concomitant medication, use of an alternative concomitant medication, increased monitoring for AEs or concomitant medication drug levels, temporary discontinuation of concomitant medications or avoiding coadministration. This presentation will cover the various mechanism of drug interactions with Paxlovid and present examples of how to manage these drug interactions.
Learning Objectives:
To outline the various mechanisms of drug interactions with Paxlovid.
To understand the contraindications of certain drugs with Paxlovid.
To understand the various approaches to manage drug-drug interactions with Paxlovid.
To illustrate the different sources of information for management of DDIs with Paxlovid.
